Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

Prognostic models for breast cancer: a systematic review

Authors: Minh Tung Phung, Sandar Tin Tin, J. Mark Elwood

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Breast cancer is the most common cancer in women worldwide, with a great diversity in outcomes among individual patients. The ability to accurately predict a breast cancer outcome is important to patients, physicians, researchers, and policy makers. Many models have been developed and tested in different settings. We systematically reviewed the prognostic models developed and/or validated for patients with breast cancer.

Methods

We conducted a systematic search in four electronic databases and some oncology websites, and a manual search in the bibliographies of the included studies. We identified original studies that were published prior to 1st January 2017, and presented the development and/or validation of models based mainly on clinico-pathological factors to predict mortality and/or recurrence in female breast cancer patients.

Results

From the 96 articles selected from 4095 citations found, we identified 58 models, which predicted mortality (n = 28), recurrence (n = 23), or both (n = 7). The most frequently used predictors were nodal status (n = 49), tumour size (n = 42), tumour grade (n = 29), age at diagnosis (n = 24), and oestrogen receptor status (n = 21). Models were developed in Europe (n = 25), Asia (n = 13), North America (n = 12), and Australia (n = 1) between 1982 and 2016. Models were validated in the development cohorts (n = 43) and/or independent populations (n = 17), by comparing the predicted outcomes with the observed outcomes (n = 55) and/or with the outcomes estimated by other models (n = 32), or the outcomes estimated by individual prognostic factors (n = 8). The most commonly used methods were: Cox proportional hazards regression for model development (n = 32); the absolute differences between the predicted and observed outcomes (n = 30) for calibration; and C-index/AUC (n = 44) for discrimination.
Overall, the models performed well in the development cohorts but less accurately in some independent populations, particularly in patients with high risk and young and elderly patients. An exception is the Nottingham Prognostic Index, which retains its predicting ability in most independent populations.

Conclusions

Many prognostic models have been developed for breast cancer, but only a few have been validated widely in different settings. Importantly, their performance was suboptimal in independent populations, particularly in patients with high risk and in young and elderly patients.
Appendix
Available only for authorised users
Literature
1.
Coleman MP, Quaresma M, Berrino F, Lutz J, de Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56.PubMedCrossRef
2.
3.
Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338:b375.PubMedCrossRef
4.
Buchholz TA, Strom EA, McNeese MD. In: Cox JD, Ang KK, editors. The breast. In Radiation oncology: Rationale, technique, results. St. Louis, Missouri: Mosby; 2003. p. 333–86.
5.
Blamey R, Ellis I, Pinder S, Lee A, Macmillan R, Morgan D, Robertson J, Mitchell M, Ball G, Haybittle J. Survival of invasive breast cancer according to the Nottingham prognostic index in cases diagnosed in 1990–1999. Eur J Cancer. 2007;43(10):1548–55.PubMedCrossRef
6.
Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, Goldstein D, Lo SK, Tattersall MH. Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol. 2004;22(9):1721–30.PubMedCrossRef
7.
Lobb EA, Kenny DT, Butow PN, Tattersall MH. Women’s preferences for discussion of prognosis in early breast cancer. Health Expect. 2001;4(1):48–57.PubMedPubMedCentralCrossRef
8.
Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19(4):453–73.PubMedCrossRef
9.
Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer Science & Business Media; 2008.
10.
Eskelinen M, Lipponen P, Papinaho S, Aaltomaa S, Kosma VM, Klemi P, Syrjanen K. DNA flow-cytometry, nuclear morphometry, mitotic indexes and steroid-receptors as independent prognostic factors in female breast cancer. Int J Cancer. 1992;51(4):555–61.PubMedCrossRef
11.
Altman DG. Prognostic models: a methodological framework and review of models for breast cancer. Cancer Investig. 2009;27(3):235–43.CrossRef
12.
Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat. 1994;30(2):117–26.PubMedCrossRef
13.
Justice AC, Covinsky KE, Berlin JA. Assessing the generalisability of prognostic information. Ann Intern Med. 1999;130(6):515–24.PubMedCrossRef
14.
Engelhardt EG, Garvelink MM, de Haes JH, Van der Hoeven JJ, Smets EM, Pieterse AH, Stiggelbout AM. Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models. J Clin Oncol. 2013;32(3):238–50.PubMedCrossRef
15.
Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMC Med. 2015;13(1):1.PubMedPubMedCentralCrossRef
16.
Moons KG, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10):e1001744.PubMedPubMedCentralCrossRef
17.
Hayden JA, Van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6.PubMedCrossRef
18.
Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427–37.PubMedCrossRef
19.
Campbell HE, Gray AM, Harris AL, Briggs AH, Taylor MA. Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer. 2010;103(6):776–86.PubMedPubMedCentralCrossRef
20.
Chao CM, Yu YW, Cheng BW, Kuo YL. Construction the model on the breast cancer survival analysis use support vector machine, logistic regression and decision tree. J Med Syst. 2014;38:106.PubMedCrossRef
21.
Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999;37(6):601–14.PubMedCrossRef
22.
Kim W, Kim KS, Lee JE, Noh DY, Kim SW, Jung YS, Park MY, Park RW. Development of novel breast cancer recurrence prediction model using support vector machine. J Breast Cancer. 2012;15(2):230–8.PubMedPubMedCentralCrossRef
23.
Lisboa PJG, Wong H, Harris P, Swindell R. A Bayesian neural network approach for modelling censored data with an application to prognosis after surgery for breast cancer. Artif Intell Med. 2003;28(1):1–25.PubMedCrossRef
24.
Ture M, Tokatli F, Omurlu IK. The comparisons of prognostic indexes using data mining techniques and cox regression analysis in the breast cancer data. Expert Syst Appl. 2009;36(4):8247–54.CrossRef
25.
Choi JP, Han TH, Park RW. A hybrid Bayesian network model for predicting breast cancer prognosis. J Kor Soc Med Informatics. 2009;15(1):49–57.CrossRef
26.
Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, Munarriz B, Martin M. Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005;94(3):265–72.PubMedCrossRef
27.
Delen D, Walker G, Kadam A. Predicting breast cancer survivability: a comparison of three data mining methods. Artif Intell Med. 2005;34(2):113–27.PubMedCrossRef
28.
Tokatli ZF, Ture M, Kurt Omurlu I, Csar Alas R, Uzal MC. Developing and comparing two different prognostic indexes for predicting disease-free survival of nonmetastatic breast cancer patients. Turkish J Med Sci. 2011;41(5):769–80.
29.
Ripley RM, Harris AL, Tarassenko L. Neural network models for breast cancer prognosis. Neural Comput Applic. 1998;7(4):367–75.CrossRef
30.
Cheng SH, Horng CF, Clarke JL, Tsou MH, Tsai SY, Chen CM, Jian JJ, Liu MC, West M, Huang AT, Prosnitz LR. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006;64(5):1401–9.PubMedCrossRef
31.
Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JFR, Blamey RW. The prognosis of small primary breast cancers. Eur J Cancer. 1999;35(6):908–12.PubMedCrossRef
32.
Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–19.PubMedCrossRef
33.
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987;56(4):489–92.PubMedPubMedCentralCrossRef
34.
van Diest PJ, Baak JP. The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients. Hum Pathol. 1991;22(4):326–30.PubMedCrossRef
35.
Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkas K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Begin LR, van’t Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, PDP P. PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7.PubMedPubMedCentralCrossRef
36.
Wishart GC, Rakha E, Green A, Ellis I, Ali HR, Provenzano E, Blows FM, Caldas C, Pharoah PDP. Inclusion of Ki67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. Eur J Surg Oncol. 2014;40(5):607.CrossRef
37.
van Belle V, van Calster B, Brouckaert O, Bempt IV, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens M, Vergote I, Van Huffel S, Neven P. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham prognostic index up to 5 years after breast Cancer diagnosis. J Clin Oncol. 2010;28(27):4129–34.PubMedCrossRef
38.
Sanghani M, Truong PT, Raad RA, Niemierko A, Lesperance M, Olivotto IA, Wazer DE, Taghian AG. Validation of a web-based predictive nomogram for ipsilateral breast tumour recurrence after breast conserving therapy. J Clin Oncol. 2010;28(5):718–22.PubMedPubMedCentralCrossRef
39.
Witteveen A, Vliegen IMH, Sonke GS, Klaase JM, Jzerman MJ, Siesling S. Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat. 2015;152(3):627–36.PubMedPubMedCentralCrossRef
40.
Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PDP. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12:R1.PubMedPubMedCentralCrossRef
41.
Chen YC, Lai HW, Wang WC, Kuo YL. Validation of breast Cancer survival prediction model with SEER database. J Integr Oncol. 2016;5(3):174.CrossRef
42.
Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J. Improved web-based calculators for predicting breast carcinoma outcomes. Breast Cancer Res Treat. 2011;128(3):827–35.PubMedCrossRef
43.
de Laurentiis M, de Placido S, Bianco AR, Clark GM, Ravdin PM. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin Cancer Res. 1999;5(12):4133–9.PubMed
44.
Jung M, Choi EH, Nam CM, Rha SY, Jeung HC, Lee SH, Yang WI, Roh JK, Chung HC. Application of the adjuvant!Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. Ann Surg Oncol. 2013;20(8):2615–24.PubMedCrossRef
45.
Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Population-based validation of the prognostic model adjuvant! For early breast cancer. J Clin Oncol. 2005;23(12):2716–25.PubMedCrossRef
46.
Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, Caldas C, Pharoah PDP. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol. 2011;37(5):411–7.PubMedCrossRef
47.
Hearne BJ, Teare MD, Butt M, Donaldson L. Comparison of Nottingham prognostic index and adjuvant!Online prognostic tools in young women with breast cancer: review of a single-institution experience. BMJ Open. 2015;5(1):e005576.PubMedPubMedCentralCrossRef
48.
Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham prognostic index applied to 9,149 patients from the studies of the Danish breast Cancer cooperative group (DBCG). Breast Cancer Res Treat. 1994;32(3):281–90.PubMedCrossRef
49.
Chollet P, Amat S, Belembaogo E, Cure H, de Latour M, Dauplat J, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Penault-Llorca F. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer. 2003;89(7):1185–91.PubMedPubMedCentralCrossRef
50.
Yadav R, Sen R, Chauhan P. Calculation of NPI score: prognosis of breast cancer. Indian J Public Health Res Dev. 2015;6(2):199–202.CrossRef
51.
D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham prognostic index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer. 2001;37(5):591–6.PubMedCrossRef
52.
Okugawa H, Yamamoto D, Uemura Y, Sakaida N, Yamada M, Tanaka K, Kamiyama Y. Prognostic factors in breast cancer: the value of the Nottingham prognostic index for patients treated in a single institution. Surg Today. 2009;8(39):738.
53.
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982;45(3):361–6.PubMedPubMedCentralCrossRef
54.
Rejali M, Tazhibi M, Mokarian F, Gharanjik N, Mokarian R. The performance of the Nottingham prognosis index and the adjuvant!Online decision making tool for prognosis in early-stage breast Cancer patients. Int J Prev Med. 2015;6:93.PubMedPubMedCentralCrossRef
55.
Masarwah A, Auvinen P, Sudah M, Dabravolskaite V, Arponen O, Sutela A, Oikari S, Kosma VM, Vanninen R. Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham prognostic index in patients with invasive breast cancer. BMC Cancer. 2016;16:833.PubMedPubMedCentralCrossRef
56.
Fan YP, Liu CL, Chiang IJ, Lin CY. Development of a prognostic nomogram for identifying those factors which influence the 2- and 5-year survival chances of Taiwanese women diagnosed with breast cancer. Eur J Cancer Care. 2011;20(5):620–6.CrossRef
57.
Wen J, Ye F, He X, Li S, Huang X, Xiao X, Xie X. Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget. 2016;7(15):21046–53.PubMedPubMedCentralCrossRef
58.
Hajage D, de Rycke Y, Bollet M, Savignoni A, Caly M, Pierga J, Horlings HM, Van de Vijver MJ, Vincent-Salomon A, Sigal-Zafrani B. External validation of Adjuvant!Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLoS One. 2011;6(11):e27446.PubMedPubMedCentralCrossRef
59.
Campbell HE, Taylor MA, Harris AL, Gray AM. An investigation into the performance of the adjuvant!Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer. 2009;101(7):1074–84.PubMedPubMedCentralCrossRef
60.
Quintyne KI, Woulfe B, Coffey JC, Gupta RK. Correlation between Nottingham prognostic index and adjuvant!Online prognostic tools in patients with early-stage breast cancer in mid-Western Ireland. Clin Breast Cancer. 2013;13(4):233–8.PubMedCrossRef
61.
Bhoo-Pathy N, Yip C, Hartman M, Saxena N, Taib NA, Ho G, Looi L, Bulgiba AM, van der Graaf Y, Verkooijen HM. Adjuvant!Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012;48(7):982–9.PubMedCrossRef
62.
Kuo Y, Chen D, Change T. Accuracy validation of adjuvant!Online in Taiwanese breast cancer patients: a 10-year analysis. BMC Med Inf Decis Mak. 2012;12(1):108.CrossRef
63.
Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Liepniece-Karele I, Purkalne G, Teibe U, Trofimovics G, Miklasevics E, Gardovskis J. Underestimated survival predictions of the prognostic tools adjuvant!Online and PREDICT in BRCA1-associated breast cancer patients. Familial Cancer. 2013;12(4):683.PubMedCrossRef
64.
Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, van’t Veer LJ, Ravdin PM. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online adjuvant! Program: a hospital-based retrospective cohort study. Lancet Oncol. 2009;10(11):1070–6.PubMedCrossRef
65.
Mojir Sheibani K, Novin K, Tabatabaeefar M, Azadeh P, Mafi AR, Moghadam S, Kamal FH, Motlagh AG. The validation study of adjuvant!Online using Iranian breast cancer data. Rep Radiother Oncol. 2013;1(3):97–102.
66.
de Glas NA, van de Water W, Engelhardt EG, Bastiaannet E, de Craen AJM, Kroep JR, Putter H, Stiggelbout AM, Weijl NI, van de Velde CJH. Validity of adjuvant!Online program in older patients with breast cancer: a population-based study. Lancet Oncol. 2014;15(7):722–9.PubMedCrossRef
67.
Wong HS, Subramaniam S, Alias Z, Taib NA, Ho GF, Ng CH, Yip CH, Verkooijen HM, Hartman M, Bhoo-Pathy N. The predictive accuracy of PREDICT: a personalized decision-making tool for southeast Asian women with breast cancer. Medicine (Baltimore). 2015;94(8):e593.CrossRef
68.
Laas E, Mallon P, Delomenie M, Gardeux V, Pierga JY, Cottu P, Lerebours F, Stevens D, Rouzier R, Reyal F. Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. Br J Cancer. 2015;112(5):912–7.PubMedPubMedCentralCrossRef
69.
de Glas NA, Bastiaannet E, Engels CC, de Craen AJM, Putter H, van de Velde CJH, Hurria A, Liefers GJ, JEA P. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. Br J Cancer. 2016;114(4):395–400.PubMedPubMedCentralCrossRef
70.
Megha T, Neri A, Malagnino V, Caruso S, Onorati M, Roviello F, Tosi P. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and oestrogen receptor signalling remain the best predictors of relapse and survival in a series of 289 cases. Cancer Biol Ther. 2010;9(4):266–73.PubMedCrossRef
71.
Sidoni A, Bellezza G, Cavaliere A, Del Sordo R, Scheibel M, Bucciarelli E. Prognostic indexes in breast cancer: comparison of the Nottingham and Adelaide indexes. Breast. 2004;13(1):23–7.PubMedCrossRef
72.
Sundquist M, Thorstenson S, Brudin L, Nordenskjöld B. Applying the Nottingham prognostic index to a Swedish breast cancer population. Breast Cancer Res Treat. 1999;53(1):1–8.PubMedCrossRef
73.
van Belle V, Decock J, Hendrickx W, Brouckaert O, Pintens S, Moerman P, Wildiers H, Paridaens R, Christiaens MR, Van Huffel S, Neven P. Short-term prognostic index for breast Cancer: NPI or Lpi. Pathol Res Int. 2010;2011:918408.
74.
Liu M, Huang W, Wang A, Huang C, Huang C, Chang T, Pi C, Yang H. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer. 2010;18(12):1553–64.PubMedCrossRef
75.
Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F. Nottingham prognostic index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer. 2011;11(1):299.PubMedPubMedCentralCrossRef
76.
Thompson SG. Why and how sources of heterogeneity should be investigated. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ; 2001. p. 157–75.CrossRef
77.
Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, Voysey M, Wharton R, Yu L, Moons KG. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;14(1):40.PubMedPubMedCentralCrossRef
78.
dos Reis FJ C, Wishart GC, Dicks EM, Greenberg D, Rashbass J, Schmidt MK, van den Broek AJ, Ellis IO, Green A, Rakha E, Maishman T, Eccles DM, PDP P. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer ReS. 2017;19(1):58.CrossRef
79.
Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28(1):1–9.PubMedCrossRef
80.
Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. BMC Med. 2010;8(1):20.PubMedPubMedCentralCrossRef
81.
Bouwmeester W, Zuithoff NPA, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, Altman DG, Moons KGM. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9(5):e1001221.PubMedCentralCrossRef
82.
Schumacher M, Hollaander N, Schwarzer G, Sauerbrei W. Prognostic factor studies. In: Crowley J, editor. Handbook of Statistics in Clinical Oncology. New York: Marcel Dekker; 2001. p. 321–78.
83.
Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69(10):1071–7.PubMed
84.
Feinstein AR. Multivariable analysis: an introduction. New Haven: Yale University press; 1996.CrossRef
85.
Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35(2):214–26.PubMedCrossRef
86.
Vergouwe Y, Moons KGM, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172(8):971–80.PubMedPubMedCentralCrossRef
87.
Peek N, Arts DGT, Bosman RJ, van der Voort PHJ, de Keizer NF. External validation of prognostic models for critically ill patients required substantial sample sizes. J Clin Epidemiol. 2007;60(5):491–501.PubMedCrossRef
88.
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606–16.PubMedCrossRef
89.
Hawkins RA, Tesdale AL, Prescott RJ, Forster T, McIntyre MA, Baker P, Jack WJL, Chetty U, Dixon JM, Killen ME, Hulme MJ, Miller WR. Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index. Br J Cancer. 2002;87(1):8–14.PubMedPubMedCentralCrossRef
90.
Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO. Nottingham prognostic index plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer. 2014;110(7):1688–97.PubMedPubMedCentralCrossRef
91.
Suen D, Chow LWC. Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham prognostic index in breast cancer. Biomed Pharmacother. 2006;60(6):293–7.PubMedCrossRef
92.
West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A. 2001;98(20):11462–7.PubMedPubMedCentralCrossRef
93.
Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM. Gene expression predictors of breast cancer outcomes. Lancet. 2003;361(9369):1590–6.PubMedCrossRef
94.
Parisi F, González AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res. 2010;12(5):R66.PubMedPubMedCentralCrossRef
95.
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N. Risk of recurrence and chemotherapy benefit for patients with node-negative, oestrogen receptor–positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol. 2011;29(33):4365–72.PubMedPubMedCentralCrossRef
96.
97.
Gomez-Ruiz JA, Jerez-Aragones JM, Munoz-Perez J, Alba-Conejo E. A neural network based model for prognosis of early breast cancer. Appl Intell. 2004;20(3):231–8.CrossRef
98.
Collan Y, Kumpusalo L, Pesonen E, Eskelinen M, Pajarinen P, Kettunen K. Prediction of survival in breast cancer: evaluation of different multivariate models. Anticancer Res. 1998;18(1B):647–50.PubMed
99.
Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31.PubMedPubMedCentralCrossRef
100.
Riley RD, Ensor J, Snell KI, Debray TP, Altman DG, Moons KG, Collins GS. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. BMJ. 2016;353:i3140.PubMedPubMedCentralCrossRef
101.
Laupacis A, Sekar N. Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA. 1997;277(6):488–94.PubMedCrossRef
102.
Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomised controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010;303(20):2058–64.PubMedCrossRef
103.
Kuehn BM. Striving for a more perfect peer review: editors confront strengths, flaws of biomedical literature. JAMA. 2013;310(17):1781–3.PubMedCrossRef
104.
Ochodo EA, de Haan MC, Reitsma JB, Hooft L, Bossuyt PM, Leeflang MM. Overinterpretation and misreporting of diagnostic accuracy studies: evidence of “spin”. Radiology. 2013;267(2):581–8.PubMedCrossRef
105.
Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605.PubMedCrossRef
106.
Lundin J. The Nottingham prognostic index- from relative to absolute risk prediction. Eur J Cancer. 2007;43(10):1498–500.PubMedCrossRef
107.
Asare EA, Liu L, Hess KR, Gordon EJ, Paruch JL, Palis B, Dahlke AR, McCabe R, Cohen ME, Winchester DP, Bilimoria KY. Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016;159(2):495–502.PubMedCrossRef
108.
Baak J, van Dop H, Kurver PHJ, Hermans JO. The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985;56(2):374–82.PubMedCrossRef
109.
Broet P, de la Rochefordiere A, Scholl SM, Fourquet A, de Rycke Y, Pouillart P, Mosseri V, Asselain B. Analysing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat. 1999;54(1):83–9.PubMedCrossRef
110.
Brown JM, Benson EA, Jones M. Confirmation of a long-term prognostic index in breast cancer. Breast. 1993;2(3):144–7.CrossRef
111.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC. Prognostic factors in breast cancer and the development of a prognostic index. Br J Surg. 1986;73(4):267–71.PubMedCrossRef
112.
Bucinski A, Baczek T, Kaliszan R, Nasal A, Krysinski J, Zaluski J. Artificial neural network analysis of patient and treatment variables as a prognostic tool in breast cancer after mastectomy. Adv Clin Exp Med. 2005;14(5):973–9.
113.
Collan Y, Eskelinen MJ, Nordling SA, Lipponen P, Pesonen E, Kumpusalo LM, Pajarinen P, Kettunen KO. Prognostic studies in breast cancer: multivariate combination of nodal status, proliferation index, tumour size, and DNA ploidy. Acta Oncol. 1994;33(8):873–8.PubMedCrossRef
114.
Fuster E, Garcia-Vilanova A, Narbona B, Romero R, Llombart-Bosch A. A statistical approach to an individualized prognostic index (IPI) for breast cancer survivability. Cancer. 1983;52(4):728–36.PubMedCrossRef
115.
Jerez Aragonés JM, Peláez Sánchez JI, Dona JM, Alba E. A neuro-fuzzy decision model for prognosis of breast cancer relapse. In: Conejo R, Urretavizcaya M, Perez-de-la-Cruz J, editors. Lecture Notes in Computer Science. Volume 3040. Berlin: Springer; 2004. p. 638–45.
116.
Jhajharia S, Varshney HK, Verma S, Kuma J. A neural network based breast cancer prognosis model with PCA processed features. Jaipur, India: Proceedings of the 2016 International Conference on Advances in Computing, Communications and Informatics (ICACCI); 2016.CrossRef
117.
118.
Liu YQ, Cheng W, Lu Z. Decision tree based predictive models for breast cancer survivability on imbalanced data. Proceedings of the 2009 3rd international conference on bioinformatics and biomedical engineering: 2009; Beijing, China. 2009.
119.
Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW. C-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991;63(3):439–43.PubMedPubMedCentralCrossRef
120.
Mazouni C, Bonnier P, Romain S, Martin PM. A nomogram predicting the probability of primary breast cancer survival at 2- and 5-years using pathological and biological tumor parameters. J Surg Oncol. 2011;103(8):746–50.PubMedCrossRef
121.
Musial M, Grodecka-Gazdecka S, Kycler W. Prognostic index in lobular breast cancer. Rep Pract Oncol Radiother. 2005;10(4):165–72.CrossRef
122.
Ni YB, Tsang JYS, Chan SK, Tse GM. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma. Ann Surg Oncol. 2014;21(9):2928–33.PubMedCrossRef
123.
Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8(1):103–12.PubMedCrossRef
124.
Putter H, van der Hage J, de Bock GH, Elgalta R, van de Velde CJ. Estimation and prediction in a multi-state model for breast cancer. Biom J. 2006;48(3):366–80.PubMedCrossRef
125.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980–91.PubMedCrossRef
126.
Sanghani M, Balk E, Cady B, Wazer D. Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool. Am J Clin Oncol. 2007;30(5):473–80.PubMedCrossRef
127.
Shek LLM, Godolphin W. Model for breast-Cancer survival - relative prognostic roles of axillary nodal status, TNM stage, oestrogen-receptor concentration, and tumour necrosis. Cancer Res. 1988;48(19):5565–9.PubMed
128.
van Nes JGH, Putter H, van Hezewijk M, Hille ETM, Bartelink H, Collette L, van de Velde CJH. EORTC breast Canc grp: tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrence. Ejso. 2010;36(7):617–24.PubMedCrossRef
129.
Wen J, Ye F, Li S, Huang X, Yang L, Xiao X, Xie X. The practicability of a novel prognostic index (PI) model and comparison with Nottingham prognostic index (NPI) in stage I-III breast cancer patients undergoing surgical treatment. PLoS One. 2015;10(11):e0143537.PubMedPubMedCentralCrossRef
130.
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Predictive value of a morphometric prognostic index in female breast cancer. Oncology. 1993;50(1):57–62.PubMedCrossRef
131.
Alexander AI, Mercer RJ, Muir IM, Bennett RC, Rennie GC. Validation of a prognostic index in breast cancer. ANZ J Surg. 1987;57(6):399–403.CrossRef
132.
Carbone A, Serra FG, Rinelli A, Terribile D, Valentini M, Bellantone R, Rossi S, Ausili-Cefaro G, Nardone L, Piantelli M, Capelli A, Ranelletti FO. Morphometric prognostic index in breast cancer. Anal Quant Cytol Histol. 1999;21(3):250–4.PubMed
133.
Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D. Nottingham prognostic index plus: validation of a clinical decision making tool in breast cancer in an independent series. J Pathol. 2016;2(1):32–40.
134.
Jung SP, Hur SM, Lee SK, Kim S, Choi M, Bae SY, Kim J, Kim MK, Kil WH, Choe J. Validation of a web-based tool to predict the ipsilateral breast tumour recurrence (IBTR! 2.0) after breast-conserving therapy for Korean patients. J Breast Cancer. 2013;16(1):97–103.PubMedPubMedCentralCrossRef
135.
Kindts I, Laenen A, Peeters S, Janssen H, Depuydt T, Nevelsteen I, Van Limbergen E, Weltens C. Validation of the Web-Based IBTR! 2.0 Nomogram to Predict for Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy. Int J Radiat Oncol Biol Phys. 2016;95(5):1477–84.PubMedCrossRef
136.
Lende TH, Janssen EAM, Gudlaugsson E, Voorhorst F, Smaaland R, van Diest P, Søiland H, Baak JPA. In patients younger than age 55 years with lymph node–negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol. 2010;29(7):852–8.PubMedCrossRef
137.
Maishman T, Copson E, Stanton L, Gerty S, Dicks E, Durcan L, Wishart GC, Pharoah P, Eccles D. An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis. Br J Cancer. 2015;112(6):983–91.PubMedPubMedCentralCrossRef
138.
Miao H, Hartman M, Verkooijen HM, Taib NA, Wong H, Subramaniam S, Yip C, Tan E, Chan P, Lee S. Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia. BMC Cancer. 2016;16(1):820.PubMedPubMedCentralCrossRef
139.
Ribelles N, Barnadas A, Lopez D, Vaquero M, Rosell R, Sanchez J. Validation of breast cancer prognostic models. Oncol Rep. 1997;4(2):419–23.PubMed
140.
Altman DG. Analysis of Survival times. In: Altman DG, editor. Practical statistics for Medical research. 1st ed. London: Chapman and Hall; 1992. p. 365–93.
141.
142.
Heller G, Mo Q. Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Anal. 2016;22(2):263–79.PubMedCrossRef
143.
Verweij PJM, van Houwelingen HC. Cross-validation in survival analysis. Stat Med. 1993;12(24):2305–14.PubMedCrossRef
Metadata
Title
Prognostic models for breast cancer: a systematic review
Authors
Minh Tung Phung
Sandar Tin Tin
J. Mark Elwood
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5442-6

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

Research article

Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials

Correction

Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study

Research article

Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes

Research article

Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification

Research article

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits